Clinical Trials Logo

Shigella Infection clinical trials

View clinical trials related to Shigella Infection.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04634513 Active, not recruiting - Shigella Infection Clinical Trials

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

Start date: September 29, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.

NCT ID: NCT04242264 Active, not recruiting - Immunisation Clinical Trials

Phase 2 Shigella Vaccine and Challenge

Start date: October 12, 2022
Phase: Phase 2
Study type: Interventional

This is a trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-pregnant females aged 18-49, inclusive. This is a two-phase study, an outpatient WRSs2 vaccination phase and an inpatient S. sonnei 53G challenge phase. After the initiation of the study, two participants had Grade 3 diarrhea and/or vomiting in the days following vaccination. The vaccination dose was reduced to 5X10^5, enrollment was changed to 2 arms and randomized 2:1 (vaccine: placebo). Participants with morbid obesity were excluded and weight loss medications prohibited. The Primary Objective of this study is to estimate combined vaccine efficacy of 2 doses of WRSs2 (10^6 cfu or 5X10^5 cfu) in preventing shigellosis, following challenge with S. sonnei strain 53G.